Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer.

Ji WangXinyang WangRui ChenMengdi LiangMinghui LiGe MaTiansong XiaShui Wang

Published in: International journal of clinical oncology (2022)

The change of CTC number during NCT has a potential to serve as a supplement to RECIST in the assessment of NCT efficacy and the prognosis of LABC patients.

Keyphrases

neoadjuvant chemotherapy
circulating tumor cells
locally advanced
rectal cancer
end stage renal disease
squamous cell carcinoma
lymph node
sentinel lymph node
radiation therapy
chronic kidney disease
ejection fraction
newly diagnosed
phase ii study
circulating tumor
prognostic factors
clinical trial
early stage